Catheter Based Intravenous Injection of Experimental Agents: A Technique for Delivering Experimental Agents Intravenously Through Jugular Vein in Mouse Model

Executive Industry Relevance

This technique enables reliable intravenous delivery of experimental agents in mouse models, supporting preclinical pharmacokinetic and pharmacodynamic studies. By providing consistent systemic access via the jugular vein, it enhances data reproducibility in early discovery workflows involving tracer-based imaging or compound screening. The method reduces variability associated with tail-vein injections, improving assay precision for target engagement and biodistribution assessments.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Scientific Value: Enables controlled delivery of pharmacological agents to assess target modulation in vivo.
• Operational Value: Supports consistent compound exposure for dose-response characterization in mechanistic studies.

Screening & Assay Development

• Scientific Value: Facilitates standardized intravenous administration for tracer-based imaging assays.
• Operational Value: Improves reproducibility of compound delivery across study groups in screening campaigns.

Translational & Preclinical Research

• Scientific Value: Supports pharmacokinetic profiling by enabling precise intravenous dosing.
• Operational Value: Allows serial blood sampling and hemodynamic monitoring when integrated with compatible systems.

Pipeline & Workflow Integration

The method fits within the discovery continuum from early target validation through lead optimization, particularly where intravenous delivery and systemic exposure are required.

• Discovery Biology: Supports hypothesis testing via controlled agent delivery to evaluate target pathway engagement.
• Screening: Enables assay-ready compound administration with reduced injection variability.
• Analytics: Provides consistent systemic exposure for quantitative readouts in imaging and biodistribution studies.
• Translational Research: Supports continuity to preclinical models by establishing reliable IV access routes.
• Enterprise Reuse: Represents a standardized surgical capability applicable across multiple pharmacology and imaging platforms.

Operational & Enterprise Impact

• Scientific Value: Increases predictive confidence in pharmacological studies through reproducible intravenous delivery.
• Operational Value: Standardizes a critical procedural step, reducing technical failure rates in vivo experiments.
• Strategic Value: Enhances go/no-go decision quality by improving data integrity in early pharmacology assessments.
• Portfolio Impact: Supports risk-adjusted advancement by generating more reliable preclinical safety and efficacy signals.

Implementation Considerations

• Requires expertise in rodent vascular access and microsurgical techniques.
• Dependent on sterile catheter supplies, microsyringes, and heating platforms for physiological maintenance.
• Necessitates cross-team standardization between surgery, imaging, and pharmacology groups for consistent execution.
• Must be adapted based on animal strain, size, and comorbid conditions affecting vascular accessibility.
• Practical limitations include potential catheter dislodgement and venous thrombosis with prolonged use, as noted in procedural constraints.

Biopharma FAQs